Publications in collaboration with researchers from Institute Catalá Oncología (21)

2024

  1. Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

    eClinicalMedicine, Vol. 71

2018

  1. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

    Breast Cancer Research and Treatment, Vol. 168, Núm. 2, pp. 357-364

2017

  1. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

    Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

  2. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy

    Journal of Clinical Oncology

2015

  1. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design

    Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315

2014

  1. Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors

    Medical Oncology, Vol. 31, Núm. 1

  2. Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy

    Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1935-1945

2013

  1. Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)

    Cell Cycle, Vol. 12, Núm. 2, pp. 225-245

  2. Eribulin mesylate in breast cancer

    Women's Health, Vol. 9, Núm. 6, pp. 517-526

2012

  1. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

    Breast Cancer Research and Treatment, Vol. 134, Núm. 3, pp. 1161-1168

2011

  1. Evidence for a link between TNFRSF11A and risk of breast cancer

    Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954

2010

  1. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: A prospective analysis of axillary or distant recurrence

    Annals of Surgical Oncology, Vol. 17, Núm. 3, pp. 772-777

  2. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer

    Oncogene, Vol. 29, Núm. 45, pp. 6071-6083

2009

  1. Aromatase inhibitors: Types, mode of action and indications

    Aromatase Inhibitors: Types, Mode of Action and Indications (Nova Science Publishers, Inc.), pp. 21-38

  2. Biological convergence of cancer signatures

    PLoS ONE, Vol. 4, Núm. 2

  3. Removal of the internal mammary sentinel node in breast cancer

    Nuclear Medicine Communications, Vol. 30, Núm. 12, pp. 962-970

2008

  1. Genetic interactions: The missing links for a better understanding of cancer susceptibility, progression and treatment

    Molecular Cancer, Vol. 7

  2. Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo

    Cancer Epidemiology Biomarkers and Prevention, Vol. 17, Núm. 4, pp. 855-863

  3. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)

    Breast Cancer Research and Treatment, Vol. 110, Núm. 3, pp. 411-416

2007

  1. Integrative analysis of a cancer somatic mutome

    Molecular Cancer, Vol. 6